Oral treprostinil use in children: a multicenter, observational experience

Oral treprostinil use in children: a multicenter, observational experience

Pulmonary arterial hypertension is a progressive, incurable disease that occurs in adults and children alike. Therapeutic options for children are limited and infrequently described, including newer agents such as treprostinil, an oral prostanoid. Herein, we describe the pooled pediatric experience...

Full description

Bibliographic Details
Main Authors:	Usama Kanaan, Nidhy P. Varghese, Ryan D. Coleman, Jeryl Huckaby, Patricia Lawrence, Lynda O. Jorgensen, Kathleen Miller-Reed, Ronald W. Day, George B. Mallory, David D. Ivy
Format:	Article
Language:	English
Published:	SAGE Publishing 2019-07-01
Series:	Pulmonary Circulation
Online Access:	https://doi.org/10.1177/2045894019862138

Similar Items

A multicenter retrospective study of patients with pulmonary hypertension transitioned from inhaled to oral treprostinil
by: Diane L. Zwicke, et al.
Published: (2021-03-01)

Characterisation of cough evoked by inhaled treprostinil and treprostinil palmitil
by: Richard W. Chapman, et al.
Published: (2021-02-01)

Oral treprostinil in transition or as add-on therapy in pediatric pulmonary arterial hypertension
by: D. Dunbar Ivy, et al.
Published: (2019-07-01)

Treprostinil for pulmonary hypertension
by: Nika Skoro-Sajer, et al.
Published: (2008-06-01)

Dosing characteristics of oral treprostinil in real-world clinical practice
by: Vijay P. Balasubramanian, et al.
Published: (2018-07-01)

Extended-release oral treprostinil in the management of pulmonary arterial hypertension: clinical evidence and experience
by: James C. Coons, et al.
Published: (2018-03-01)

Inhaled treprostinil: a therapeutic review
by: Channick RN, et al.
Published: (2012-01-01)

Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension
by: Ifeoma Oriaku, et al.
Published: (2020-03-01)

Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension
by: Pugliese SC, et al.
Published: (2016-01-01)

Experiences with treprostinil in the treatment of pulmonary arterial hypertension
by: Amanda R. Stream, et al.
Published: (2012-10-01)

Successful management of an inadvertent excessive treprostinil overdose
by: Hohenforst-Schmidt W, et al.
Published: (2013-03-01)

Treprostinil Iontophoresis In Idiopathic Pulmonary Arterial Hypertension
by: Tonelli, Adriano R.
Published: (2015)

Long-term study of oral treprostinil to treat pulmonary arterial hypertension: dosing, tolerability, and pharmacokinetics
by: R. James White, et al.
Published: (2020-12-01)

A pilot study of oral treprostinil pharmacogenomics and treatment persistence in patients with pulmonary arterial hypertension
by: James C. Coons, et al.
Published: (2021-04-01)

The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension
by: Tobias Gessler, et al.
Published: (2011-06-01)

Impact of four times daily dosing of oral treprostinil on tolerability and daily dose achieved in pulmonary hypertension
by: James C. Coons, et al.
Published: (2017-11-01)

Right ventricular afterload predicts long-term transition from parenteral to oral treprostinil in pulmonary arterial hypertension
by: Travis Maestas, et al.
Published: (2018-08-01)

The Rapid Initiation, Titration, and Transition from Intravenous to Oral Treprostinil in a Patient with Severe Pulmonary Arterial Hypertension
by: James Benjamin Gleason, et al.
Published: (2015-01-01)

Combination therapy with riociquat and inhaled treprostinil in inoperable and progressive chronic thromboembolic pulmonary hypertension
by: John W. Swisher, PhD, MD, et al.
Published: (2017-01-01)

Intravenous treprostinil via an implantable pump in pediatric pulmonary arterial hypertension
by: Susanna Desole, et al.
Published: (2018-12-01)

Implantable system for treprostinil: a real-world patient experience study
by: Shelley Shapiro, et al.
Published: (2020-04-01)

Pharmacokinetics and tolerability of LIQ861, a novel dry-powder formulation of treprostinil
by: Robert Roscigno, et al.
Published: (2020-11-01)

Clinical Utility of Treprostinil and Its Overall Place in the Treatment of Pulmonary Arterial Hypertension
by: Shireen Mirza, et al.
Published: (2012-07-01)

Clinical Utility of Treprostinil and Its Overall Place in the Treatment of Pulmonary Arterial Hypertension
by: Shireen Mirza, et al.
Published: (2012-01-01)

Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension
by: Asuka Furukawa, et al.
Published: (2017-10-01)

An implantable pump Lenus pro® in the treatment of pulmonary arterial hypertension with intravenous treprostinil
by: Marcin Kurzyna, et al.
Published: (2017-12-01)

Treprostinil reduces mitochondrial injury during rat renal ischemia-reperfusion injury
by: Meiwen Ding, et al.
Published: (2021-09-01)

Development and Characterization of Treprostinil Palmitil Inhalation Aerosol for the Investigational Treatment of Pulmonary Arterial Hypertension
by: Adam J. Plaunt, et al.
Published: (2021-01-01)

Treprostinil inhibits proliferation and extracellular matrix deposition by fibroblasts through cAMP activation
by: Christopher Lambers, et al.
Published: (2018-01-01)

Mechanism of anti-remodelling action of treprostinil in human pulmonary arterial smooth muscle cells.
by: Christopher Lambers, et al.
Published: (2018-01-01)

Treprostinil alleviates hepatic mitochondrial injury during rat renal ischemia-reperfusion injury
by: Joyce Hou, et al.
Published: (2021-11-01)

Orotracheal treprostinil administration attenuates bleomycin-induced lung injury, vascular remodeling, and fibrosis in mice
by: Ioanna Nikitopoulou, et al.
Published: (2019-11-01)

Cost-Effectiveness of Treprostinil Versus Epoprostenol in Patients with Pulmonary Arterial Hypertension: A Canadian Analysis
by: Thomas R Einarson, et al.
Published: (2005-01-01)

Impact of inhaled treprostinil on risk stratification with noninvasive parameters: a post hoc analysis of the TRIUMPH and BEAT studies
by: Adriano R. Tonelli, et al.
Published: (2020-12-01)

Flow rate variance of a fully implantable pump for the delivery of intravenous treprostinil in pulmonary arterial hypertension
by: Manuel J. Richter, et al.
Published: (2020-03-01)

Periprocedural safety and outcome after pump implantation for intravenous treprostinil administration in patients with pulmonary arterial hypertension
by: Jan C. Kamp, et al.
Published: (2021-05-01)

Pediatric subcutaneous treprostinil site maintenance and pain control strategies from the Pediatric Pulmonary Hypertension Network
by: Emma O. Jackson, et al.
Published: (2021-03-01)

Implantable system for treprostinil and lung transplantation: case series from delivery for pulmonary arterial hypertension study
by: Jeremy P. Feldman, et al.
Published: (2021-03-01)

Novel dose–response analyses of treprostinil in pulmonary arterial hypertension and its effects on six-minute walk distance and hospitalizations
by: Gautam Ramani, et al.
Published: (2020-06-01)

BREEZE: Open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension
by: Bajwa, A.A, et al.
Published: (2022)